News
Migraine: NICE recommends further prevention option
BMJ 2020; 371 doi: https://doi.org/10.1136/bmj.m4052 (Published 19 October 2020) Cite this as: BMJ 2020;371:m4052
- Elisabeth Mahase
- The BMJ
Galcanezumab, a new migraine drug, has been recommended by the National Institute for Health and Care Excellence as part of draft guidance.1
Published on 15 October, the guidance said that galcanezumab (marketed by Eli Lilly as Emgality) can be used to prevent migraine in adults who have at least four days with migraine each month and in whom at least three previous preventive treatments …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £157 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£30 / $37 / €33 (excludes VAT)
You can download a PDF version for your personal record.